Marbotab 20 mg Tablets for Dogs and Cats

Main information

  • Trade name:
  • Marbotab 20 mg Tablets for Dogs and Cats
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Marbotab 20 mg Tablets for Dogs and Cats
    Netherlands
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • marbofloxacin
  • Therapeutic area:
  • Cats, Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0431/001
  • Authorization date:
  • 21-12-2012
  • EU code:
  • UK/V/0431/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:March2013

AN:01688/2011

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

MarbotabP20mgtabletsfordogsandcats

ListofagreednamesintheMemberStateswhereproductisauthorized.

Italy,Germany,France,TheNetherlands,

Belgium,Hungary MarbotabP20mgtabletsfordogsand

cats

Denmark MarbotabP,20mgtablets,fordogsand

cats

UnitedKingdom,Ireland,Poland,Spain,

Austria Marbotab20mgtabletsfordogsandcats

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activesubstance:

Marbofloxacin 20mg

Excipients:

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Tablet

Beigetabletswithwhitespeckled,cross-snap-tab.

Thetabletscanbedividedintoquarters.

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogs,cats

4.2 Indicationsforuse,specifyingthetargetspecies

Treatmentofinfectionscausedbystrainsofmicroorganismssusceptibleto

marbofloxacin.

Indogs:

Skinandsofttissueinfections(skinfoldpyoderma,impetigo,folliculitis,

furunculosis,cellulitis);

Urinarytractinfections(UTI)associatedornotwithprostatitis;

Respiratorytractinfections.

Issued:March2013

AN:01688/2011

Page2of6

Incats:

Skinandsofttissueinfections(wounds,abscesses,phlegmons);

Upperrespiratorytractinfections.

Seesection5.1,Pharmacodynamicpropertiesforfurtherinformationonspecific

targetpathogens.

4.3 Contraindications

Marbofloxacinshouldnotbeusedindogsagedlessthan12months,orlessthan18

monthsforexceptionallylargebreedsofdogs,suchasGreatDanes,Briard,Bernese

BonvierandMastiffs,withalongergrowthperiod.

Donotuseincatsagedlessthan16weeks.

Donotuseincasesofhypersensitivitytofluoroquinolonesoranyoftheexcipientsof

theproduct.

Donotuseincaseofresistanceagainstquinolones,since(almost)completecross-

resistanceexistsagainstandotherfluoroquinolones.

Notsuitableforinfectionsresultingfromstrictanaerobes,yeastorfungi.

4.4Specialwarnings

None.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Thefluoroquinoloneshavebeenshowntoinduceerosionofarticularcartilagein

juveniledogsandcareshouldbetakentodoseaccuratelyespeciallyinyoung

animals.

Thefluoroquinolonesarealsoknownfortheirpotentialneurologicalsideeffects.

Cautionsuseisrecommendedindogsandcatsdiagnosedassufferingfrom

epilepsy.

AlowurinarypHcouldhaveaninhibitoryeffectontheactivityofmarbofloxacin.

Officialandlocalantimicrobialpoliciesshouldbetakenintoaccountwhentheproduct

isused.

Fluoroquinolonesshouldbereservedforthetreatmentofclinicalconditionswhich

haverespondedpoorly,orareexpectedtorespondpoorly,tootherclassesof

antimicrobials.

Wheneverpossible,fluoroquinolonesshouldonlybeusedbasedonsusceptibility

testing.

UseoftheproductdeviatingfromtheinstructionsgivenintheSmPCmayincrease

theprevalenceofbacteriaresistanttothefluoroquinolonesandmaydecreasethe

effectivenessoftreatmentwithotherquinolonesduetothepotentialforcross

resistance.

Issued:March2013

AN:01688/2011

Page3of6

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Incaseofaccidentalingestionseekmedicaladviceimmediatelyandshowthe

packageleafletorthelabeltothephysician.Weargloveswhenhandlingordividing

tablets.Washhandsafteruse.

Peoplewithknownhypersensitivitytofluoroquinolonesshouldavoidusingthis

product.

4.6Adversereactions(frequencyandseriousness)

Atthetherapeuticrecommendeddosage,nosevereside-effectsaretobeexpected.

Mildsideeffectssuchasvomiting,allergicreactions,softeningoffaeces,modification

ofthirstortransientincreaseinactivitymayoccasionallyoccur.Thesesignscease

spontaneouslyaftertreatmentanddonotnecessitatecessationoftreatment.

Nolesionsoftheparticularjointswereencounteredinclinicalstudiesatthe

recommendeddoserate.

However,jointpainand/orneurologicalsymptoms(ataxia,aggressiveness,

convulsion,depression)mayoccurinrareoccasions.

Allergicreactionshavebeenobserved(temporaryskinreactions)duetothe

histaminereleasethatmayoccur.

4.7Useduringpregnancy,lactationorlay

Safetyinpregnantandlactatingdogsandcatshavenotbeenestablished.Studiesin

pregnantratsandrabbitsshowednosideeffectsonpregnancy.

Useinpregnantandlactatinganimalsshouldbeinaccordancewiththebenefit/risk

assessmentperformedbytheresponsibleveterinarian.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Fluoroquinolonesareknowntointeractwithorallyadministeredcations(aluminium,

calcium,magnesium,iron).Insuchcases,thebioavailabilitymaybereduced.

Donotuseincombinationwithtetracyclines,macrolidesbecauseofthe

potentialantagonisteffect.

Whenadministeredtogetherwiththeophylline,thehalf-lifeandthustheplasma

concentrationoftheophyllineincrease.Hence,thedoseoftheophyllineshouldbe

reduced.

4.9 Amountstobeadministeredandadministrationroute

Fororaladministration.Therecommendeddoserateis2mg/kg/dinasingledaily

administration.Toensureacorrectdosagebodyweightshouldbedeterminedas

accuratelyaspossibletoavoidunderdosing.Tabletsmaybedividedalongscore

linestofacilitateaccuratedosing.

Issued:March2013

AN:01688/2011

Page4of6

Durationoftreatment:

Dogs:

Inskinandsofttissueinfections,treatmentdurationisatleast5days.Dependingon

thecourseofthedisease,itmaybeextendedupto40days.

Inurinarytractinfectionsnotrelatedtoprostatitisorepididymitis,treatmentduration

isatleast10days.Inothercases,dependingonthecourseofthedisease,itmaybe

extendedupto28days.

Inrespiratoryinfections,treatmentdurationisatleast7days.Dependingonthe

courseofthedisease,itmaybeextendedupto21days.

Cats:Forskinandsofttissueinfections(wounds,abscesses,phlegmons)treatment

durationis3to5days.

Forupperrespiratoryinfections,treatmentdurationis5days.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Overdosagemaycausecartilagedamageinthejointsandacutesignsintheformof

neurologicaldisorders,whichshouldbetreatedsymptomatically.

4.11Withdrawalperiod(s)

Notapplicable

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse,Fluoroquinolone

ATCvetcode:QJ01MA93

5.1 Pharmacodynamicproperties

Marbofloxacinisasynthetic,bactericidalantimicrobial,belongingtothe

fluoroquinolonegroup,whichactsbyinhibitionofDNAgyrase.Itiseffectiveagainsta

widerangeofGrampositivebacteria(Staphylococci(S.aureusandS.intermedius)

andStreptococci)andGramnegativebacteria(Escherichiacoli,Citrobacterfreundii,

Enterobactercloacae,Proteusspp,Klebsiellapneuminiae,Pasteurellamulticida,

Pseudomonasaeruginosa,Bordetellabronchiseptica)aswellasMycoplasmaspp.

CasesofresistancehavebeenobservedinStreptococcus.

StrainswithMIC≤1µg/mlaresensitivetomarbofloxacinwhereasstrainswithMIC≥

4µg/mlareresistanttomarbofloxacin.

Resistancetofluoroquinolonesoccursbychromosomalmutationwiththree

mechanisms:decreaseofthebacterialwallpermeability,expressionofeffluxpump

ormutationofenzymesresponsibleformoleculebinding.

Marbofloxacinisnotactiveagainstanaerobes,yeastsorfungi.

Issued:March2013

AN:01688/2011

Page5of6

5.2Pharmacokineticparticulars

Afteroraladministrationindogsandcatsattherecommendeddoseof2mg/kg,

marbofloxacinisreadilyabsorbedandreachesmaximalplasmaconcentrationsof1.5

µg/mlwithin2hours.

Itsbioavailabilityiscloseto100%.

Itisweaklyboundtoplasmaproteins(lessthan10%),extensivelydistributedandin

mosttissues(liver,kidney,skin,lung,bladder,digestivetract)itachieveshigher

concentrationsthaninplasma.Marbofloxaciniseliminatedslowly(eliminationhalf-life

is14hoursindogsand10hoursincats)predominantlyintheactiveforminurine

(2/3)andfaeces(1/3).

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Lactosemonohydrate

Cellulose,powdered

Crospovidone

Colloidalanhydroussilica

Calciumbehenate

Yeast,deactivated

Artificialbeefflavour(PC-0125)

6.2Incompatibilities

Noneknown

6.3Shelflife

Shelflifeoftheveterinaryproductaspackagedforsale:2years.

Shelflifeofquarteredtablets:72hours.

6.4.Specialprecautionsforstorage

Storetheblistersintheoriginalcontainer.

Ifthetabletsaredivided,theremainingquartersshouldbekeptintheblisterpack.

Anyquarteredtabletsremainingafter72hoursshouldbediscarded.

6.5Natureandcompositionofimmediatepackaging

Aluminium-polyamide/Aluminium/PVCblisterpackscontaining10tablets.

Theblisterpacksareavailableincartonsof20,50,100and200tablets.

Notallpacksizesmaybemarketed.

Issued:March2013

AN:01688/2011

Page6of6

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfrom

suchveterinarymedicinalproductsshouldbedisposedofinaccordancewith

localrequirements.

7. MARKETINGAUTHORISATIONHOLDER

CP-PharmaHandelsgesellschaftmbH

Ostlandring13

31303Burgdorf

Germany

8. MARKETINGAUTHORISATIONNUMBER

Vm20916/4018

9. DATEOFFIRSTAUTHORISATION

27March2013

10.DATEOFREVISIONOFTHETEXT

March2013

PROHIBITIONORSUPPLYSALEANDORUSE

Tobesuppliedonlyonveterinaryprescription.

Approved:27/03/2013

5-12-2018

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods of Vancouver, WA is voluntarily recalling 933 packages of Cow Pie fresh frozen meats for dogs and cats, produced in August 2017, because it has the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

26-11-2018

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species.

FDA - U.S. Food and Drug Administration

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

20-11-2018

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

FDA - U.S. Food and Drug Administration

24-10-2018

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, of Versailles, OH is recalling all products lots manufactured from February 27, 2018 through July 20, 2018, as a precaution because they have the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

22-6-2018

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

FDA - U.S. Food and Drug Administration

7-6-2018

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Heartworm disease can be fatal to pets, but it is also preventable. Learn more about the dangers of heartworm disease and the importance of year-round prevention.

FDA - U.S. Food and Drug Administration

2-5-2018

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

FDA - U.S. Food and Drug Administration

26-11-2018

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health technologies.

FDA - U.S. Food and Drug Administration

4-9-2018

Agenda:  Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda: Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda of CHMP written procedure*20-23 August 2018

Europe - EMA - European Medicines Agency

22-8-2018

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye:  http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz . pic.twitter.com/ecJErFeiSH

FDA - U.S. Food and Drug Administration

20-7-2018

Agenda:  Agenda - CAT agenda of the 18-20 July 2018 meeting

Agenda: Agenda - CAT agenda of the 18-20 July 2018 meeting

Committee for Advanced Therapies (CAT) agenda for the meeting on 18-20 July 2018

Europe - EMA - European Medicines Agency

29-6-2018

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit  https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFriday pic.twitter.com/JWK672XtdI

FDA - U.S. Food and Drug Administration